2026 SITC Biotech Strategic Meeting at the NYSE

Friday, June 26 at the New York Stock Exchange

Join investors and leaders from biotechnology, biopharma, academia, and regulatory agencies for high-level strategic dialogue on the future of cancer immunotherapy.

Join the waitlist

Thank you to our program organizers.

Program Co-Chair
David Kaufman, MD, PhD
Third Rock Ventures

Program Co-Chair
Holger Kissel, PhD
BioNTech SE

Jarrett Rieger, Esq
Moffitt Cancer Center

SITC Biotech Committee Co-Chair
Alexandra Snyder, MD
Merck

Program Co-Chair
Zhen Su, MD, MBA
Marengo Therapeutics

Kasia Urbanska, PhD
Bristol Myers Squibb

Sign up below to get the latest program news.

Designed to foster candid discussion and cross-sector collaboration, the 2026 SITC Biotech Strategic Meeting will focus on critical opportunities and challenges shaping the next phase of innovation in the field.

Program Description

The annual biotech strategic meeting at the NYSE convenes a highly curated group of biotech executives, investors and drug development leaders to explore the most pressing strategic questions shaping the future of immuno-oncology.

The program will feature discussions on late-stage and commercial biotech strategy, emerging modalities such as in vivo cell therapies, AI-enabled drug development and the evolving global regulatory and financing landscape.

Designed to foster meaningful dialogue and high-value connections, this forum offers a unique opportunity to engage directly with leaders driving innovation and deal making across the biotech ecosystem.

Registration Rates

In-Person Registration Rates

	Early Rate	Regular Rate
Industry Member	$400.00	$450.00
Industry Non-Member	$800.00	$850.00
Member	$200.00	$250.00
Non-Member	$400.00	$450.00
Student Member	$50.00	$100.00
Student Non-Member	$100.00	$150.00